NEW YORK, May 21, 2015 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of IsoRay, Inc. ("IsoRay" or the "Company") (NYSE MKT: ISR). Such investors are advised to contact Robert S. Willoughby at email@example.com or 888-476-6529, ext. 237.
The investigation concerns whether IsoRay and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
On May 21, 2015, TheStreet.com website published a report which stated that "IsoRay does a poor job selling radioactive 'seeds' for use in cancer radiation therapy. To make up for the inability to deliver revenue growth -- and prop up its stock price -- IsoRay issues a lot of promotional press releases, some of which take liberties with clinical data using clever, selective editing."
On this news, shares of IsoRay fell $1.10 per share, to 2.02, or more than 35.26%, on May 21, 2015.
The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Florida, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 70 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.
Robert S. Willoughby
SOURCE Pomerantz LLP